{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"AMBASSADOR","nct_id":"NCT03244384","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ambassador-nct03244384. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"AMBASSADOR","arms":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, CT urography, and/or MRI throughout the trial. Patients may also undergo a cystoscopy and blood sample collection during screening and on study.","label":"Arm A (pembrolizumab)","type":"EXPERIMENTAL"},{"description":"Patients undergo observation. Patients undergo a CT scan, CT urography, and/or MRI throughout the trial. Patients may also undergo a cystoscopy and blood sample collection during screening and on study.","label":"Arm B (observation)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-31","type":"ESTIMATED"},"conditions":["Localized Renal Pelvis and Ureter Urothelial Carcinoma","Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma","Locally Advanced Ureter Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Stage II Bladder Urothelial Carcinoma AJCC v6 and v7","Stage II Renal Pelvis and Ureter Cancer AJCC v7","Stage II Ureter Cancer AJCC v7","Stage III Bladder Urothelial Carcinoma AJCC v6 and v7","Stage III Renal Pelvis and Ureter Cancer AJCC v7","Stage III Ureter Cancer AJCC v7"],"enrollment":{"count":739,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Clinical Observation","type":"OTHER"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"CT Urography","type":"PROCEDURE"},{"name":"Cystoscopy","type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Pharmacological Study","type":"OTHER"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"}],"last_update":"2026-10-01","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From randomization to the date of death from any cause, assessed up to 5 years"},{"measure":"Disease-free survival","timeFrame":"From randomization to the first metastatic recurrence (presence of any recurrent disease), or death, whichever occurs first, assessed up to 5 years"}],"references":[{"citation":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15.","pmid":"39282902","type":"DERIVED"}],"start_date":{"date":"2017-11-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","url":"https://clinicaltrials.gov/study/NCT03244384"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ambassador-nct03244384"}